Cargando…
PARP1 Upregulation in Recurrent Oral Cancer and Treatment Resistance
First-line treatments for oral cancer typically include surgery, radiation, and in some cases, chemotherapy. Radiation and oral cancer chemotherapeutics confer cytotoxicity largely by inducing DNA damage, underscoring the importance of the cellular DNA damage repair and response pathways in cancer t...
Autores principales: | Wang, Feifei, Gouttia, Odjo G., Wang, Ling, Peng, Aimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769238/ https://www.ncbi.nlm.nih.gov/pubmed/35071239 http://dx.doi.org/10.3389/fcell.2021.804962 |
Ejemplares similares
-
The MASTL-ENSA-PP2A/B55 axis modulates cisplatin resistance in oral squamous cell carcinoma
por: Gouttia, Odjo G., et al.
Publicado: (2022) -
A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma
por: Li, Hui, et al.
Publicado: (2022) -
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
por: Rose, Maddison, et al.
Publicado: (2020) -
PRSS1 Upregulation Predicts Platinum Resistance in Ovarian Cancer Patients
por: Xing, Linan, et al.
Publicado: (2021) -
RECQ1 Promotes Stress Resistance and DNA Replication Progression Through PARP1 Signaling Pathway in Glioblastoma
por: Zhang, Jing, et al.
Publicado: (2021)